Pioneers Stem Cell Therapy Poland veterinary dogs orthopedics, neurology, nefrology.wmv
Lubelskie Centrum Ma #322;ych Zwierz #261;t Using 10 years of knowledge in small animal Stem Cell Therapy in USA from one of the leading Referral Specialists Veterinary Clinic Pioneers of Stem Cell Therapy in Nefrology (with hemodialysis units) Orthopedics Neurology in Poland Any contact at komorkimacierzyste@lcmz.pl Each case is treated individually in terms of stem cell therapy. If there is any contraindication to the use of the therapy it wont be given.

By: MrLCMZ

More here:
Pioneers Stem Cell Therapy Poland veterinary dogs orthopedics, neurology, nefrology.wmv - Video

Recommendation and review posted by Bethany Smith

SILVER SPRING, Md. and VIENNA, Austria, Feb. 15, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, announced today its subsidiary, Austrianova Singapore Pte. Ltd. (ASPL) has reported the successful establishment of a research "cell bank" that will ultimately be used to obtain the numbers of cells necessary for conducting the Company's late-phase clinical trials in patients with advanced, inoperable, pancreatic cancer.

The research cell bank was established by ViruSure GmbH, an Austrian Contract Research Organization located in Vienna, Austria. The genetically augmented human cells in the cell bank are the same as those used in the two successfully completed mid-phase clinical trials in advanced non-resectable pancreatic cancer patients previously reported by Nuvilex.

ViruSure is an important international biosafety company in the biotechnology community with substantial expertise in cell culture, virus, prion, and other infectious agent testing, as well as cell growth and assessment capabilities. ViruSure assessed the purity and sterility of our cells. Before the cell bank was established, the cells were tested and shown to be free of contamination by mycoplasma, a type of bacteria that can be toxic to humans. The validation that the cells in the cell bank are "mycoplasma-free" is a prerequisite for further expansion of the cell line required for Nuvilex's late-phase clinical studies in advanced pancreatic cancer that are currently in preparation. Nuvilex is proud to announce that completion of this stage successfully showed the cells were mycoplasma-free.

Since that initial assessment, ViruSure has been carrying out the amplification of these same cells on a "fast track" basis. These cells will ultimately be used for encapsulation and subsequently implanted in patients for the treatment of advanced, inoperable pancreatic cancer.

"We are excited that the initial steps required for the commencement of additional clinical trials of our encapsulated cell therapy in advanced pancreatic cancer have been made possible through the establishment of this cell bank," said Dr. Brian Salmons, CEO of ASPL.

In discussions with ViruSure they stated, "We are pleased to be involved in achieving this important milestone for Austrianova Singapore and Nuvilex that will enable the future development and evaluation of their treatment for pancreatic cancer." The ViruSure state-of-the-art facilities for amplifying cells under GLP (Good Laboratory Practices) conditions and their capabilities in testing for contaminants arena were contributing factors in it being chosen to carry out this activity.

Dr. Robert F. Ryan, President and CEO of Nuvilex said, "We are very pleased by the thoroughness with which ViruSure has completed the first assessment and are now carrying out the amplification of these important cells for use in cancer treatments. The professionalism shown by both ViruSure and ASPL and the timely fashion in which this important milestone was achieved are extremely gratifying. Nuvilex is committed to advancing this project through the necessary additional clinical trials to the market place so that our novel pancreatic cancer treatment can be made available for the treatment of this devastating disease."

About Nuvilex

Nuvilex, Inc. (NVLX) has been a provider of all-natural products for many years. The company has been expanded to increase its natural product-based footprint and will continue to make advances as we move forward. We are an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. New developments by our company and subsidiaries will be substantial as we have been working on many fronts to move us forward. Our company's offerings will ultimately include cancer, diabetes and other treatments using the Company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development.

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

See the rest here:
Nuvilex Reports Successful Establishment of Initial Research Cell Bank to Support Late-Phase Pancreatic Cancer ...

Recommendation and review posted by Bethany Smith

A FEDERAL Court decision highlights the need for patent laws to be changed so corporations can't monopolise genetic material needed to detect and treat cancer, the Cancer Council says.

In the Federal Court on Friday, Brisbane woman Yvonne D'Arcy and Cancer Voices Australia lost their fight against the patenting of a human gene linked to breast and ovarian cancer.

Theby brought their action against Myriad Genetics Inc, the owner of the patent, and Melbourne-based Genetic Technologies Ltd, which holds the exclusive licence to conduct the tests in Australia.

The case related to mutations of an isolated gene, associated with an increased risk of hereditary breast and ovarian cancers, known as BRCA1.

Cancer Council chief Ian Olver said the ruling "reflected a lack of progress in patent law, which was based on centuries-old principles but being applied to rapidly changing technology".

"If we don't change the law now to protect the community from gene monopolies ... a handful of commercial interests (will own) the genetic materials essential to cancer detection and treatment," Professor Olver said.

He thanked Ms D'Arcy for launching the legal challenge and said he expected more challenges against biotechnology companies from consumers "until the law is changed".

Prof Olver said patents shouldn't be granted over genes as their discovery was not an invention.

If companies were able to patent genes it could create a monopoly and stymie research.

"The benefit in not being able to patent the gene is that you have a whole lot of companies competing for research to look for new cancer treatments and new cancer tests," Prof Olver told AAP on Friday.

View post:
Call for change in gene patent laws

Recommendation and review posted by Bethany Smith

Medical experts have called for the law to be changed amid fears cancer research may be stymied following a ruling which allows private companies to patent isolated human genes.

Cancer activists also believe treatment options might be limited in the wake of the landmark ruling handed down by Federal Court Justice John Nicholas on Friday, allowing two biotech companies to retain their patent over mutations to an isolated gene known as BRCA1.

People who have these mutations on BRCA1 have been found to have an increased risk of breast and ovarian cancer.

Cancer survivor Yvonne D'Arcy and Cancer Voices Australia had taken the case against Myriad Genetics Inc, the owner of the patent, and Melbourne-based Genetic Technologies Ltd, which holds the exclusive licence to conduct the tests in Australia.

They argued the patent was invalid, as patents protected inventions and not discoveries.

They said gene patents would increase the cost of treating cancer and could limit treatment options.

Myriad argued the case did not involve a patent for a gene but for an "artificial construct".

It is the first time an Australian court has ever had to consider whether isolated human genes can be patented and Justice Nicholas found that isolation of the gene from the human body was the product of human intervention.

As a result, he ruled isolated gene sequences were therefore patentable.

It means the patent of Myriad Genetics Inc and the licence to the patent held in Australia by Genetic Technologies Limited remain in place.

Visit link:
Calls for law change after gene ruling

Recommendation and review posted by Bethany Smith

A 'Field of Women' formed to raise funds for Breast Cancer Network Australia at Melbourne Cricket Ground on May 7, 2010.

STORY HIGHLIGHTS

(CNN) -- Can companies patent human genes? It was the question considered by an Australian federal court judge who on Friday ruled that a U.S. biotech company was within its rights to hold Australian patent 686004.

That patent covers mutations of the human gene BRCA1 which point to a greater hereditary risk of breast and ovarian cancer.

The same gene, along with another, BRCA2, is at the center of a high-profile lawsuit in the U.S. set to be heard by the Supreme Court in April.

That lawsuit argues that patents on human genes violate the First Amendment and U.S. patent law because genes are "products of nature" and therefore can't be patented, according to the American Civil Liberties Union (ACLU).

The Australian Federal Court defeat was a crushing blow for cancer campaigners who have been fighting to have the patent declared invalid since the case was first filed in June 2010.

"I won't give up the fight because this is too important for future generations of people who at some point in their lives may need testing and treatment for cancers and other diseases," said breast cancer survivor Yvonne D'Arcy, one of the parties in the case.

Rebecca Gilsenan of Maurice Blackburn Lawyers, who represented D'Arcy and Cancer Voices Australia, said: "We are disappointed in this ruling but it is not necessarily the end of the issue in a legal or policy sense.

"We think there may be grounds to appeal, and that there's a reasonable chance that we will make that decision in the next week or two."

Read the original post:
Australian court backs claim to own breast cancer gene

Recommendation and review posted by Bethany Smith

YAKIMA, Wash. (AP) -- Supporters argued that an initiative requiring genetically engineered foods to be labeled gives Washington state consumers information they need to make informed choices at the grocery store. Opponents countered that the move is unnecessary: These foods are perfectly healthy, and if consumers don't want them, they can buy organic.

Lawmakers heard both sides of the debate Thursday in Olympia, during a public hearing for Initiative 522. The ballot measure would require food and seeds produced entirely or partly through genetic engineering and sold in Washington to be labeled as such, beginning July 1, 2015. Raw foods that are not packaged separately would have to be labeled on retail shelves.

A similar initiative failed narrowly with voters in California last year.

More than 60 countries require such foods to be labeled, but the U.S. isn't one of them. Only Alaska has enacted legislation requiring the labeling of genetically engineered fish and shellfish products.

Supporters of the Washington initiative pointed to the growing global agreement about genetic engineering and genetically modified organisms, noting that other countries have recognized concerns about new allergens and changes in nutrition levels, among other things.

Yet the U.S. government leaves it to the corporations developing the technology to determine their products' safety self-regulation that most Americans, if they understood it, would be uncomfortable with, said Ken Cook of the nonprofit Environmental Working Group.

"If big, corporate agribusiness were so convinced there were no health risks to GMOs, they would be more than willing to label them," said Patricia Michael, who spoke in support of the measure. "Instead, they want to hide them from us."

And for good reason, she added.

"We were told that DDT was harmless, that saccharin was harmless," she said. "We have a right to know what we're eating."

Opponents argued that the requirement is likely to raise food prices and that labeling should only be required at the federal level.

Read more here:
Both sides of GMO fight at Wash. Senate hearing

Recommendation and review posted by Bethany Smith

Public release date: 15-Feb-2013 [ | E-mail | Share ]

Contact: Beata Mostafavi bmostafa@umich.edu 734-764-2220 University of Michigan Health System

ANN ARBOR, Mich. Researchers don't know the exact cause of Behet's disease, a chronic condition that leads to oral and genital sores and serious complications such as blindness, but new research brings better understanding to what makes some people more susceptible to being affected.

In one of the most extensive genetic analyses of Behet's disease, a University of Michigan-led, international team of researchers has identified novel gene variants in the inflammatory disorder and uncovered data that could apply to studies of other diseases. The results appear in the journal Nature Genetics.

"This disease is associated with significant complications and because it is not well understood, treatment options are limited," says lead author Amr Sawalha, M.D., associate professor of internal medicine in the division of rheumatology at the U-M Medical School.

"We were able to identify and localize robust genetic risk factors associated with Behet's disease in a way that will hopefully bring us a step closer to better understanding this devastating illness."

The UMHS research, a collaboration that includes researchers from Turkey, Italy, Germany and the Netherlands, identifies how a specific group of genes are linked to Behet's disease. The disease can affect people from all ethnicities, but has an increased prevalence along the ancient "Silk Road" in East Asia, Turkey, and the Mediterranean and Middle Eastern countries.

The disorder causes chronic inflammation in blood vessels throughout the body and affects many organs, including the eyes, brain, skin, joints and the digestive system. Some symptoms may include mouth and genital ulcers, eye inflammation and reduced vision, skin rashes and lesions, joint swelling, abdominal pain and diarrhea.

Behet's disease may also cause inflammation in the brain, which could cause headaches, fever, poor balance or stroke. Inflammation in veins and large arteries could also lead to other complications, such as aneurysms.

One of the major genetic risk factors of the disease is believed to be a specific form of a gene on chromosome 6 in the HLA region (an inherited group of genes known as human leukocyte antigen). The new study shows that contrary to the belief that genetic risk in this region is most strongly tied to a form of the gene HLA-B (called HLA-B*51) there are actually at least four independent genetic risk regions within the HLA linked to the disease. and the risk previously attributed to the HLA-B*51 protein itself is explained by a gene variant outside the HLA-B gene. Researchers have long studied the phenomenon of why certain forms of HLA are associated with autoimmune and inflammatory disorders and the severity of those disorders.

Originally posted here:
Researchers uncover new findings on genetic risks of Behçet's disease

Recommendation and review posted by Bethany Smith

Newswise ANN ARBOR, Mich. Researchers dont know the exact cause of Behet's disease, a chronic condition that leads to oral and genital sores and serious complications such as blindness, but new research brings better understanding to what makes some people more susceptible to being affected.

In one of the most extensive genetic analyses of Behet's disease, a University of Michigan-led, international team of researchers has identified novel gene variants in the inflammatory disorder and uncovered data that could apply to studies of other diseases. The results appear in the journal Nature Genetics.

This disease is associated with significant complications and because it is not well understood, treatment options are limited, says lead author Amr Sawalha, M.D., associate professor of internal medicine in the division of rheumatology at the U-M Medical School.

We were able to identify and localize robust genetic risk factors associated with Behets disease in a way that will hopefully bring us a step closer to better understanding this devastating illness.

The UMHS research, a collaboration that includes researchers from Turkey, Italy, Germany and the Netherlands, identifies how a specific group of genes are linked to Behets disease. The disease can affect people from all ethnicities, but has an increased prevalence along the ancient Silk Road in East Asia, Turkey, and the Mediterranean and Middle Eastern countries.

The disorder causes chronic inflammation in blood vessels throughout the body and affects many organs, including the eyes, brain, skin, joints and the digestive system. Some symptoms may include mouth and genital ulcers, eye inflammation and reduced vision, skin rashes and lesions, joint swelling, abdominal pain and diarrhea.

Behets disease may also cause inflammation in the brain, which could cause headaches, fever, poor balance or stroke. Inflammation in veins and large arteries could also lead to other complications, such as aneurysms.

One of the major genetic risk factors of the disease is believed to be a specific form of a gene on chromosome 6 in the HLA region (an inherited group of genes known as human leukocyte antigen).The new study shows that contrary to the belief that genetic risk in this region is most strongly tied to a form of the gene HLA-B (called HLA-B*51) there are actually at least four independent genetic risk regions within the HLA linked to the disease. and the risk previously attributed to the HLA-B*51 protein itself is explained by a gene variant outside the HLA-B gene.

Researchers have long studied the phenomenon of why certain forms of HLA are associated with autoimmune and inflammatory disorders and the severity of those disorders.

This HLA region has an incredibly significant role in many diseases. Its also one of the most complicated areas of the human genome, which is why its so difficult to analyze, Sawalha says. This is an extensive way to look at the HLA region that can be also applied to other diseases. We can now identify and localize the risks within this complex HLA region more accurately than ever before, which opens the door to further developments.

See the original post here:
Researchers Uncover New Findings on Genetic Risks of Chronic Inflammatory Disorder Behcet's Disease

Recommendation and review posted by Bethany Smith

CANBERRA (Reuters) - An Australian court ruled on Friday that two technology companies could hold a patent on genetic material related to cancer, in a case similar to one before the U.S. Supreme Court that has implications for gene-based medicine worldwide.

Cancer support groups said the finding could stifle new breast cancer research and treatment. Australia's Federal Court ruled that U.S. company Myriad Genetics Inc and Melbourne-based Genetic Technologies Ltd had the right to hold a patent on human genetic material.

The material is known as BRCA1, a mutation associated with higher risk of hereditary breast and ovarian cancer.

The U.S. Supreme Court will consider the same issue, which could affect millions of people worldwide, later this year.

In Australia, trial judge John Nicholas found the material could be subject to a patent because it could not exist naturally on its own inside or outside the human body.

He found those who develop a way of isolating it should have the right to a patent and to reap the financial rewards.

"It would lead to very odd results if a person whose skill and effort culminated in the isolation of a micro-organism ... could not be independently rewarded by the grant of a patent," Nicholas said.

The finding disappointed cancer support groups, consumer organization Cancer Voices, and Brisbane woman Yvonne D'Arcy, who challenged the patents in the Federal Court.

Lawyer Rebecca Gilsenan, who represented D'Arcy and Cancer Voices, said the decision could limit new research because researchers would need the companies' permission to study BRCA1.

"In its isolated form, it is private property of the companies. If researchers want to access it now, they need to get permission or pay for it," Gilsenan told Reuters.

Original post:
Australian court supports patents on human genes

Recommendation and review posted by Bethany Smith

NeuroDevNet: FASD Research from the Lab to the Community
Many are familiar with NeuroDevNet, one of Canada #39;s Research Centres of Excellence, and their research in genetics and structural alterations in the brain as a result of fetal alcohol exposure. What you may not be aware of is how far beyond this their research in FASD goes. Knowledge translation, neuroethics and neuroinformatics are other research arms that bring a variety lenses to the issue of FASD. The presentation will introduce NeuroDevNet, a Network of Centres of Excellence in developmental neuroscience. NeuroDevNet is the first trans-Canada initiative dedicated to studying children #39;s brain development from both basic science and clinical perspectives. NeuroDevNet #39;s FASD team is engaged in an interdisciplinary research project that will investigate the relationship between genetics, structural alterations in the brain, and neurobehavioural outcomes in children impacted by FASD. Join us as we walk through an overview of the spectrum of FASD research and findings being generated by NeuroDevNet. Presenters Dr. James Reynolds B.Sc., Ph.D - Dr. James Reynolds is a graduate of Queen #39;s University (B.Sc., 1982, Ph.D, 1987). After obtaining his doctorate, he completed postdoctoral training at the Addiction Research Foundation and the University of Toronto. Dr. Reynolds #39; research interests over the past 20 years have centred around studies on the effects of alcohol on brain function. In particular, his current research program is focused on understanding the mechanisms of ...

By: CAPHCTv

View post:
NeuroDevNet: FASD Research from the Lab to the Community - Video

Recommendation and review posted by Bethany Smith

UTEP Headlines Newscast 02.15.13.
IT #39;S FRIDAY, FEBRUARY 15, 2013. HELLO, I #39;M VERONIQUE MASTERSON. HERE #39;S WHAT YOU NEED TO KNOW ABOUT WHAT #39;S HAPPENING AT THE UNIVERSITY OF TEXAS AT EL PASO. ### MARK YOUR CALENDARS -- WE HAVE SEVERAL EXCITING EVENTS COMING UP! THIS WEEKEND THE UTEP MEN #39;S BASKETBALL TEAM WILL FACE UCF AT 7 PM AT THE DON HASKINS CENTER. THE WOMEN WILL ALSO FACE UCF, BUT ON THE ROAD IN ORLANDO. ### THE UNIVERSITY WILL CELEBRATE PRESIDENT #39;S DAY WITH THE DEDICATION OF THE NEW FLAGPOLE NEAR THE PSYCHOLOGY BUILDING. THE NEW LOCATION, LIGHTING SYSTEM AND ELEVATION ABOVE THE PLANNED CENTENNIAL PLAZA WILL MAKE IT A HIGHLY VISIBLE LANDMARK. ### TUESDAY, UTEP WILL MARK THE GRAND OPENING OF THE RESEARCH AND ACADEMIC DATA CENTER AND THE RESEARCH CLOUD. THE CENTER IS HOME TO UTEP #39;S HIGH-PERFORMANCE COMPUTING EQUIPMENT, GIVING FACULTY MEMBERS THE RESOURCES THEY NEED TO PERFORM HIGH-CAPACITY COMPUTING. ITS RECENT EXPANSION AND RELOCATION ALLOW FOR GREATER ACCESS, MORE EQUIPMENT, AND A WIDER VARIETY OF SERVICES, INCLUDING REMOTE OR "CLOUD" ACCESS TO COMPUTING PROCESSES AND DISASTER RECOVERY BACK-UP SYSTEMS. IBM DISTINGUISHED ENGINEER AND MASTER INVENTOR ROMELIA FLORES WILL BE ON CAMPUS FOR THE GRAND OPENING. AFTER WHICH SHE WILL KICK OFF THE SPRING CENTENNIAL LECTURE SERIES AT THE UNDERGRADUATE LEARNING CENTER. HER LECTURE "HOW SMARTER HITS THE STREETS: TECHNOLOGY ENABLING TODAY #39;S CITIES" WILL BE FREE AND OPEN TO THE PUBLIC. ### ACCORDING TO RECENT STUDIES BY MAHESH NARAYAN, PH.D., UTEP ASSOCIATE PROFESSOR ...

By: UTEP

Originally posted here:
UTEP Headlines Newscast 02.15.13. - Video

Recommendation and review posted by Bethany Smith

Irradia (Ziria Radium) How to live with Radiation: Consciousness Genetics
Irradia (Ziria Radium) - How to Live with Radiation: Consciousness and Genetics PROGRAM NOTES exopolitics.blogs.com

By: Alfred Lambremont Webre

Go here to see the original:
Irradia (Ziria

Recommendation and review posted by Bethany Smith

Booktopia presents: The Rosie Project by Graeme Simsion (Interview with Caroline Baum)
The feel-good hit of 2013, The Rosie Project is a classic screwball romance. Simsion #39;s book has been sold to 30 different countries and advances have well exceeded $1 million. Don Tillman, professor of genetics, has never been on a second date. Then a chance encounter gives him an idea. He will design a questionnaire mdash;a sixteen-page, scientifically researched document mdash;to find the perfect partner. She will most definitely not be a barmaid, a smoker, a drinker or a late-arriver. Rosie Jarman is all these things. She is strangely beguiling, fiery and intelligent. And she is also on a quest of her own. She #39;s looking for her biological father, a search that a certain DNA expert might just be able to help her with mdash;even if he does wear quick-dry clothes and eat lobster every single Tuesday night. About the Author Graeme Simsion was born in 1956. He is an IT consultant and data analyst with an international reputation. He has taught at four Australian universities and is currently a Senior Research Fellow at Melbourne University. He is a founder of Pinot Now, a wine importer and distributor, and is married to Anne, a professor of psychiatry who writes erotic fiction. They have two children. In 2007, Graeme completed his PhD in information systems and enrolled in the professional screenwriting course at Royal Melbourne Institute of Technology. He has made a number of short films and his screenplay, The Rosie Project, won the Australian Writers Guild / Inception Award for Best ...

By: booktopiabooks

Read more from the original source:
Booktopia presents: The Rosie Project by Graeme Simsion (Interview with Caroline Baum) - Video

Recommendation and review posted by Bethany Smith

So Close! (The Hidden) Part 8
Hello friends, and welcome to The Hidden. As an IRIS agent you are entrusted to contain (Kill) Subject 617, a creation that has gone rouge and is on a war path... Bring him to justice! As the Hidden, you have a one objective... To live, by any means necessary. Obviously to do this you must KILL! Protect yourself from the research facility that made you this way. Story of the Hidden, In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage: Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception ...

By: Ravenus Flamingo

Continue reading here:
So Close! (The Hidden) Part 8 - Video

Recommendation and review posted by Bethany Smith

Signal Transduction Dance
Baylor University students in Dr. Moehnke #39;s Molecular Genetics class illustrate the MAP kinase and Ras signal transduction systems through the art of DANCE!

By: mhmoehnke

More here:
Signal Transduction Dance - Video

Recommendation and review posted by Bethany Smith

Gun Bros 2 Coming Soon to iOS! (Gameplay Trailer)
Untold years after the first TOOL wars, the Tyrannical Oppressors Of Life have returned to finish the job. Only the Freakishly Rugged Advanced Genetics Galactic Enforcement Division (FRAGGED) agents Percy and Francis Gun stand in their way. Armed with a new array of highly advanced and ridiculously destructive weapons, the Gun Bros are once again defending the galaxy from the TOOL insurgency. It is a time to innovate and eradicate. The last conflict has left both sides scrambling to rebuild their armories. Old Xplodium mines have been reopened and even decommissioned factories are once again roaring to life as the conflict escalates. It is up to Percy and Francis to stop this threat from reemerging with an even more devastating arsenal of killing machines. The Gun Bros are back and, once again, responsible for defending the galaxy. Luckily, they #39;ve got access to a host of new gear that will help them defeat TOOL REAL-TIME MULTIPLAYER! Battle the TOOL hordes with your Gamecenter friends, head over to the all-new Endless Mode and check it out! NEW GUNS MODS! Choose from a broad range of weapons; from pistols rocket launchers to new and improved laser weapons shotguns. Collect MODS and strap them on your weapon to gain secondary, tertiary and even quaternary fire modes! Players can even unleash multiple MODS at once! MEGA BOSS BATTLES! Battle against the Pus Titan, Maullusk and The Broliminator! These monstrous bosses are enough to get any Bro excited... THE ...

By: glumobilegames

Original post:
Gun Bros 2 Coming Soon to iOS! (Gameplay Trailer) - Video

Recommendation and review posted by Bethany Smith

Dr. Epstein - 5 months Post-Op Surgical Hairline Advancement (SHA)
Dr. Epstein discusses the results of a patient 5 months post-op SHA. The patient #39;s main concern was her overly high hairline, approximately 9-10 sonometers (centimeters) from the brow. This was shortened to 5.5-6 sonometers, 4 sonometers of advancement with a barely detectable incision. The hairline advancement/lowering procedure can lower the overly high hairline whether due to genetics, hair loss, or prior surgery such as browlifts. Most commonly it is performed on women, where the high forehead can be shortened. In addition, it is possible to actually change the shape of the hairline, making it more oval or rounded by filling in the upper temporal/side regions, creating a more feminine appearance. This is a procedure in which Dr. Epstein specializes, performing them on average two to three times weekly, mostly on patients who travel in for the procedure. For more information please email info@fhrps.com or visit us at http://www.womenscenterforhairloss.com or http://www.foundhair.com

By: foundhair

Original post:
Dr. Epstein - 5 months Post-Op Surgical Hairline Advancement (SHA) - Video

Recommendation and review posted by Bethany Smith

SizeGenetics Review - DON #39;T Buy SizeGenetics Until You Watch this Video
sizegeneticsreviews.us -- Click the link to the left for a $50 discount on SizeGenetics! Try to find the best penis extender online and you #39;ll definitely land on a SizeGenetics review. The next step without doubt is actually to find out methods to add these inches. Other than that, a majority of guys out there lose their self-confidence if they possess an average-sized package. That is why penile enhancement methods are introduced to help them build their self-esteem and make them feel good about themselves. The precise traction control and tension tested device ensures that the correct amount of pressure is applied from day 1 for larger gains than with any other device. The cost of the hospital, the operation room and the clinical doctors runs into thousands and not wrongly so. - Danger - Penis surgical operation is a dangerous solution of male organ growth. Loss of blood flow, discoloration in the penis shaft and head region and also problems are widespread examples of penis medical operation going wrong. SizeGenetics relies on none of these. By utilizing the ancient theory of traction that is used in many surgical procedures, this device is able to not only enlarge your penis but also straighten out any curve you may suffer from. On the other hand, a minor discomfort during initial use is one common drawback of the penis extender, together with skin irritation for some (that is, if your skin is too sensitive). Is it visible? No. SizeGenetics products are not just used ...

By: reviewsyoucanuse99

Go here to read the rest:
SizeGenetics Review - DON'T Buy SizeGenetics Until You Watch this Video - Video

Recommendation and review posted by Bethany Smith

Obama is the New Bush: 23% of US Illiterate! States Face $3Trillion Pension Hole
My commentary on the painful similarities between Obama and Bush, 23% of Americans being illiterate, the shameful deficit, unfunded pensions and more. 23% Of America Is Illiterate One in five Americans lacks the basic reading skills beyond a 4th grade level - are you one of them? http://www.zerohedge.com Parents Complain About School Ad Excluding Whites From Tutoring Program denver.cbslocal.com Google #39;flaw #39; puts users #39; details on display http://www.news.com.au all of So Cal was on locked down because of ONE GUY. All of this manpower and mayhem of one guy. It #39;s incredible. http://www.youtube.com Obama Calls South Korean President Lee After North #39;s Nuclear Test http://www.rttnews.com North Korea Says it Has Successfully Conducted a Nuclear Test abcnews.go.com Chinese Troop Movements Signal War? ntdtv.org US Trade Deficit Shrinks To Smallest In Nearly Three Years http://www.rttnews.com Fed #39;s Holdings of US Gov #39;t Debt Hit Record $1696691000000; Up 257% Under Obama cnsnews.com The coming pension crisis: States face a $3 trillion funding gap. http://www.mybudget360.com Myriad Genetics Wins Australia Bid to Patent Human Genes http://www.bloomberg.com Food stamps http://www.fns.usda.gov Obama #39;s Turn in Bush #39;s Bind http://www.nytimes.com Obama to announce 34K troops to be home in 1 year Obama won #39;t announce troop numbers beyond 2014 in Tuesday #39;s speech and has not yet made that decision, apnews.myway.com

By: DEMCAD

Follow this link:
Obama is the New Bush: 23% of US Illiterate! States Face $3Trillion Pension Hole - Video

Recommendation and review posted by Bethany Smith

The humpback whale has recovered significantly from commercial whaling in the past several decades. An accurate pre-whaling population estimate is considered important in considering future management decisions and protection for the species in North Atlantic waters. Credit: Salvatore Cerchio/Wildlife Conservation Society.

Published: Feb. 14, 2013 at 7:36 PM

NEW YORK, Feb. 14 (UPI) -- North Atlantic humpback whales have recovered from years of whaling, but a precise pre-whaling number estimate is key to defining that recovery, scientists say.

To that end, researchers from Stanford University, the Wildlife Conservation Society, the American Museum of Natural History and other organizations are using genetic analysis to estimate the pre-whaling population of North Atlantic humpback whales.

They estimate humpbacks existed in numbers of more than 100,000, a figure lower than previously calculated but still two to three times higher than pre-whaling estimates based on catch data from whaling records, a WCS release said Thursday.

"We're certain that humpback whales in the North Atlantic have significantly recovered from commercial whaling over the past several decades of protection, but without an accurate size estimate of the pre-whaling population, the threshold of recovery remains unknown," Stanford researcher Kristen Ruegg said. "We now have a solid, genetically generated estimate upon which future work on this important issue can be based."

Humpbacks, which can reach 50 feet in length, were hunted for centuries by commercial whaling fleets in all the world's oceans, with their numbers in the North Atlantic eventually being reduced to just hundreds before whaling bans went into effect and the creatures began a remarkable comeback.

"We have spent a great deal of effort refining the techniques and approaches that give us this pre-whaling number," Steve Palumbi of Stanford said. "It's worth the trouble because genetic tools give one of the only glimpses into the past we have for whales."

Read more here:
Genetics used to gauge whale comeback

Recommendation and review posted by Bethany Smith

Myriad Genetics, owner of patents related to genes linked to hereditary cancer risks, has won an Australian court ruling allowing it to patent isolated DNA, a first in Australia.

Federal Court Justice John Nicholas today in Sydney dismissed a 2010 lawsuit aimed to stop Myriad and Genetic Technologies from patenting a gene mutation associated with an increased risk of breast and ovarian cancers.

This case is groundbreaking, Rebecca Gilsenan, a lawyer at Melbourne-based Maurice Blackburn, the firm representing the opponents, said in an e-mailed statement before todays ruling. No Australian court has been asked to consider the question of whether isolated human genes are patentable.

The issue has divided the global medical community with groups including the Association for Molecular Pathology and the American College of Medical Genetics arguing that Myriad is attempting to get legal ownership of parts of the human body.

Advertisement

The issue returns to the US Supreme Court for a second time this year after the US Court of Appeals for the Federal Circuit twice ruled that genes can be patented.

The US high court agreed on Nov. 30 to hear the Association for Molecular Pathologys appeal.

Royalty demands

Some scientists argue they have been stymied in researching new medicines and treatments because they may come up against demands for royalties or letters demanding they stop using patented inventions.

Companies such as Genomic Health have argued they cant attract investment dollars if they cant protect their research from competitors.

View original post here:
Myriad Genetics wins bid to patent human genes

Recommendation and review posted by Bethany Smith

Mario Tama/Getty Images

Some scientists argue they have been stymied in researching new medicines and treatments because they may come up against demands for royalties or letters demanding they stop using patented inventions.

Myriad Genetics Inc., owner of patents for genes linked to cancer risks, won an Australian court ruling allowing it to patent isolated DNA, a first in the country, with the U.S. Supreme Court set to hear a similar case.

Federal Court Justice John Nicholas today in Sydney dismissed a 2010 lawsuit aimed at stopping Myriad and Genetic Technologies Ltd. from patenting a gene mutation associated with an increased risk of breast and ovarian cancers.

The issue has divided the global medical community with groups including the Association for Molecular Pathology and the American College of Medical Genetics arguing that Myriad is attempting to get legal ownership of parts of the human body. The conflict returns to the U.S. Supreme Court this year after the U.S. Court of Appeals for the Federal Circuit twice ruled that genes can be patented. The U.S. high court agreed on Nov. 30 to hear the Association for Molecular Pathologys appeal.

Rebecca Gilsenan, a lawyer at Melbourne-based Maurice Blackburn, the firm representing the opponents, said after the Australian decision that they will have to review the 41-page judgment before determining whether to appeal.

Were really interested in the U.S. Supreme Court hearing, Gilsenan said. Well be watching it very closely.

The Australian ruling will allow patents on anything that is artificial, without consideration of the biological material from which it derived, Luigi Palombi, a patent lawyer and author of Gene Cartels: Biotech Patents in the Age of Free Trade, said in an e-mailed statement.

No matter how important it is to identify a gene linked to a disease, its still not something that Myriad or anyone else has invented, Palombi said. Politicians must now change the law to prevent patenting of genetic materials, he said.

Some scientists argue they have been stymied in researching new medicines and treatments because they may come up against demands for royalties or letters demanding they stop using patented inventions. Companies such as Genomic Health Inc. have argued they cant attract investment dollars if they cant protect their research from competitors.

Original post:
Myriad Genetics Wins Australian Bid to Patent Human Genes

Recommendation and review posted by Bethany Smith

By Serena Gordon HealthDay Reporter

THURSDAY, Feb. 14 (HealthDay News) -- In news that might one day help humans who struggle with type 1 diabetes every day, Spanish researchers report that a single session of gene therapy injections cured five beagle puppies who had the blood sugar disease.

Even four years later, the dogs showed no signs of diabetes.

"Our data represent the first demonstration of long-term correction of diabetes in a large animal model using gene transfer," the scientists wrote in the Feb. 7 online issue of Diabetes.

However, the dogs all had a chemically induced version of diabetes that's meant to model human type 1 diabetes.

In humans, type 1 diabetes is an autoimmune disease, which means the body's own immune system mistakenly attacks healthy cells as though they were bacteria or viruses.

In the case of type 1 diabetes, the immune system destroys the insulin-producing beta cells located in the pancreas. Insulin is a hormone that's needed to transport glucose into the body's cells to be used as fuel. Glucose is sugar that comes from the carbohydrates you consume. Carbohydrates are nutrients found in a variety of foods, including fruits, vegetables, breads and sweets.

Once the beta cells are destroyed, the body no longer makes insulin (or makes very little of the hormone), and anyone with type 1 diabetes needs insulin injections or an insulin pump for the rest of their lives.

However, insulin needs change constantly, depending on the type and amount of food eaten and level of physical activity. Even emotions can affect insulin levels. Too little insulin can cause high blood sugar levels, while too much insulin can cause low blood sugar levels. Neither condition is healthy and, if severe enough, either can cause death.

In the current study, the researchers developed a gene therapy that served two purposes: one was to sense the amount of glucose in skeletal muscles and the other was to release insulin. This research group had already tested this therapy in mice, where it was found to be successful in controlling blood sugar levels.

See the article here:
Lucky Dogs Get Shot at Diabetes Cure

Recommendation and review posted by Bethany Smith

Travel and Spinal Cord Injury: Finding Your Comfort Zone
Three individuals with spinal cord injuries talk about their experiences traveling after injury and share tips for making travel successful. Presented on March 8, 2011 at the University of Washington Medical Center.

By: UWSpinalCordInjury

Read the rest here:
Travel and Spinal Cord Injury: Finding Your Comfort Zone - Video

Recommendation and review posted by sam

Developing neuroprosthetic treatments for spinal cord injury
Dr. Chet Moritz conducts research in brain-computer interfaces and neuroprosthetic technology. The goal of his research is to develop systems that can bypass damaged areas of the spinal cord and restore voluntary control of movement to paralyzed muscles. His research uses a combination of animal and human studies. In this presentation, Dr. Moritz summarizes the state of the art in this field and describes his study using brain activity to control Functional Electrical Stimulation (FES) to stimulate the muscles of a paralyzed wrist. In addition to direct muscle stimulation, another promising approach is intraspinal stimulation. This technique was nearing its first clinical trial at the time of this talk. Dr. Moritz explains intraspinal stimulation and his work generating movements of the hand and arm.

By: UWSpinalCordInjury

See the original post:
Developing neuroprosthetic treatments for spinal cord injury - Video

Recommendation and review posted by sam